Actively Recruiting

Phase 4
Age: 18Years - 85Years
All Genders
NCT06084234

National Liver Cancer Screening Trial

Led by University of Texas Southwestern Medical Center · Updated on 2025-11-26

5500

Participants Needed

18

Research Sites

574 weeks

Total Duration

On this page

Sponsors

U

University of Texas Southwestern Medical Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.

CONDITIONS

Official Title

National Liver Cancer Screening Trial

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 85 years with cirrhosis from any cause or chronic hepatitis B with PAGE-B score over 9 within 12 months
  • Eligible for liver cancer screening as determined by doctor or site investigator
  • Able to give informed consent
  • Expected to live longer than 6 months as judged by doctor or investigator
Not Eligible

You will not qualify if you...

  • Child Pugh class C cirrhosis
  • History or symptoms of liver or bile duct cancer
  • Solid liver nodule 1 cm or larger on ultrasound within 9 months without follow-up CT/MRI showing it is benign
  • AFP level over 20 ng/mL within 6 months without CT or MRI excluding suspicious lesions
  • Recent diagnosis of certain liver imaging results (LR-3 ≥1 cm, LR-4, LR-5, LR-M) within 6 months
  • Active cancer other than non-melanoma skin cancer or slow-growing cancers under surveillance within 2 years
  • Planned use of CT or MRI for liver cancer surveillance
  • History of liver shunt procedure (TIPS), Fontan liver disease, cardiac cirrhosis, or solid organ transplant
  • Currently listed for liver transplant
  • Alcohol-associated hepatitis diagnosed within 3 months
  • Signs of acute Wilson disease
  • Recent active cholangitis in patients with primary sclerosing cholangitis
  • Known habitual non-adherence to medical procedures or research
  • For HIV patients, CD4 count below 100 cells/mm3 within 60 days
  • Known pregnancy at consent
  • Current use of warfarin medication

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

University of Southern California

Los Angeles, California, United States, 90089

Actively Recruiting

2

Stanford University

Redwood City, California, United States, 94063

Actively Recruiting

3

Kaiser Permanente

Roseville, California, United States, 95661

Actively Recruiting

4

University of California, San Francisco

San Francisco, California, United States, 94117

Actively Recruiting

5

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

6

Indiana University

Indianapolis, Indiana, United States, 46202

Actively Recruiting

7

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

8

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

9

Henry Ford Health System

Detroit, Michigan, United States, 48202

Actively Recruiting

10

Hennepin Healthcare

Minneapolis, Minnesota, United States, 55415

Actively Recruiting

11

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

12

The Feinstein Institutes, Northwell Health, Inc.

Manhasset, New York, United States, 11030

Actively Recruiting

13

University of North Carolina

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

14

Case Western Reserve University

Cleveland, Ohio, United States, 44106

Actively Recruiting

15

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

16

UT Southwestern Medical Center and Parkland Hospital

Dallas, Texas, United States, 75390

Actively Recruiting

17

Baylor College of Medicine

Houston, Texas, United States, 77021

Actively Recruiting

18

Virginia Commonwealth University

Richmond, Virginia, United States, 23219

Not Yet Recruiting

Loading map...

Research Team

A

Amit Singal, MD, MS

CONTACT

S

Sneha Deodhar, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SCREENING

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here